Formal synthesis of (−)-pereniporin B and (−)-cinnamosmolide

Alexandru Ciocarlanab*, Aculina Aricua, Nicon Ungura, Andrei Biriiaca, Mihai Coltsa, Alina Nicolescu, Calin Deleanuc and Nicoleta Vornicud

aInstitute of Chemistry, Academy of Sciences of Moldova, Academiei Street 3, MD-2028 Chisinau, Republic of Moldova; b'Petru Poni’ Institute of Macromolecular Chemistry of the Romanian Academy, Aleea Grigore Ghica Voda 41A, RO-700487 Iasi, Romania; c'Costin D. Nenitescu’ Centre of Organic Chemistry, Romanian Academy, Splaiul Independentei 202B, P.O. Box 35-98, RO-060023 Bucharest, Romania; dMetropolitan Center of Research T.A.B.O.R., Closca 9, RO-700066 Iasi, Romania

(Received 29 January 2014; final version received 1 June 2014)

The paper describes a new pathway for an efficient synthesis of natural and bioactive drimanic compounds (−)-pereniporin B (1) and (−)-cinnamosmolide (2) from ketodiol 7, an intermediate obtained before from accessible labdane diterpenoid (+)-larixol (3). The key step involves allylic bromination of acetate 8 with N-bromosuccinimide. The in vitro antimicrobial and antifungal activities of all compounds are also reported. Their structures were confirmed by both spectroscopic data and chemical transformations.

Keywords: (−)-pereniporin B; (−)-cinnamosmolide; (+)-larixol; formal synthesis

1. Introduction

Drimane sesquiterpenoids have a wide range of biological activities (Jansen & de Groot 2004; Fraga 2013). Drimanic lactone pereniporin B (1) and its acetate cinnamosmolide (2) were isolated from several species of Canellaceae family: Cinnamosma fragrans (Canonica et al. 1967), Capsicodendron dinisii (Mahmoud et al. 1980) and Cinnamosma madagascariensis (Harinantenaina et al. 2008), from the culture filtrate of Perenniporia medullaepanis (Basidiomycete) (Kida et al. 1986), and from the stem bark of Warburgia ugandensis (Warburgia) (Rajab & Ndegva 2000), Figure 1.

It has been reported that pereniporin B (1) is a plant growth inhibitor (Kida et al. 1986), while cinnamosmolide (2) showed in vitro antifungal activity against dermatophites Tricophyton rubrum, Tricophyton mentagrophythes and Microsporum gypseum (Canonica et al. 1969).

Both metabolites were found to exhibit cytotoxic activity: pereniporin B (1) against friend leukaemia cells (F5-5) (Morioka et al. 1985) and cinnamosmolide (2) against the 9KB5 carcinoma in cell culture (Mahmoud et al. 1980).  

First total syntheses of racemic pereniporin B (1) and cinnamosmolide (2) were performed in nine steps starting from a drimanic allylic alcohol, with ~5% overall yield (Naito et al. 1980). Since then several syntheses of 1 in an optically active form have been described, involving 28 steps (1.8% yield) and (S)-3-hydroxy-2,2-dimethyl-1-cyclohexanone as starting material (Mori & Takaishi 1989). The enantioselective synthesis of pereniporin B (1) was performed (Burke et al. 1991) in 19 steps (~3% yield) from an aliphatic vinylsulphoxide. Another accessible natural diterpenoid zamoranic acid was used for six-step synthesis of pereniporin B (1) in 11% yield by Urones et al. (1994). The only nine-step synthesis of
cinnamosmolide (2) was reported in 14% overall yield by transformation of uvidin A (Garlaschelli et al. 1991).

Herein we wish to report a new and efficient pathway for the synthesis of (−)-pereniporin B (1) and (−)-cinnamosmolide (2) from (−)-larixol (3) via key intermediate ketodiol 7. It must be mentioned that previously compound 7 was isolated from natural sources in low amounts (Hayes et al. 1996; Zhou et al. 2011).

2. Results and discussion

A valuable intermediate ketodiol 7 was obtained earlier during the synthetic transformation of uvidin A into (−)-cinnamodial (Garlaschelli & Vidari 1989). The same diol 7 was prepared during conversion of (−)-larixol (3) into highly functionalised drimanes (Lagnel et al. 2000). (−)-Larixol (3) can be easily isolated from oleoresin of larch (Larix sp.) and due to hydroxyl group at C-6 is a suitable starting material for the synthesis of drimanes functionalised at the same position (Mills 1973). Recently we reported a new synthesis of natural drimanic compounds (−)-albrassitriol and (−)-6-epi-albrassitriol from (−)-larixol (3) where ketodiol 7 was obtained in 28.3% overall yield as indicated in Scheme 1 (Vlad et al. 2013).

It is clear that more applications of dienone 7 for the synthesis of drimanes can be developed, especially when an easy fuctionalisation of the allylic methyl group C-12 can be accomplished. This has been achieved already by the allylic oxidation with selenium oxide (Garlaschelli & Vidari 1989). In our group the same transformation has been carried out using allylic bromination followed by the substitution of bromide by an acetate group as indicated in Scheme 2.

The acetylation of the primary hydroxyl group of 7–8 under standard conditions was made prior to the allylic bromination in order to prevent undesired oxidation at this position. The allylic bromination of 8 with N-bromosuccinimide (NBS) and subsequent replacement of bromine by treatment with KOAc gave 10 in high yield (Scheme 2).
The acetate groups in 10 were hydrolysed leading to the known triol 11 (Urones et al. 1997; Zhou et al. 2011), which after oxidation of the least hindered hydroxyl group with MnO₂ followed by spontaneous cyclisation and oxidation led to lactone 12 (Kubo et al. 1983). The transformation of precursor 12 into pereniporin B (1) was reported earlier (Burke et al. 1991). It includes treatment of lactone 12 with DIBAL-H, followed by Fetizon’s oxidation of the resulted lactols. Cinnamosmolide (2) can be prepared from pereniporin B (1) by its acetylation under standard conditions (Canonica et al. 1969).

Compounds 7–12 were screened for their in vitro antifungal and antibacterial activity against pure cultures of three fungi species (Aspergillus niger, Penicillium frequentans, Alternaria alternata) and against both Gram-negative (Pseudomonas aeruginosa) and Gram-positive bacteria (Bacillus polymyxa). According to these assays, bromide 9 exhibited good antifungal activity with a minimum inhibitory concentration (MIC) value of 0.85 mg/mL in comparison with the reference compound caspafungin (0.42 mg/mL) and good antimicrobial activity 0.90 mg/mL in comparison with the reference compound kanamycin (0.50 mg/mL). Noteworthy, the antifungal activity of bromide 9 is higher than that reported for cinnamosmolide (2) (Canonica et al. 1969).

3. Experimental

3.1. General experimental procedure

Melting points (m.p.) were taken on a Boethius (VEB Analytik, DDR) hot stage apparatus. Optical rotations were determined on a Perkin-Elmer 241 polarimeter (Perkin-Elmer, Norwalk, CT, USA) with a 1 dm microcell, in CHCl₃. IR spectra were obtained on Bio-Rad-Win-IR (Bio-Rad, Cambridge, MA, USA) and Perkin-Elmer spectrometers (Perkin-Elmer, Norwalk, CT, USA). ¹H and ¹³C NMR spectra were recorded in CDCl₃ on Bruker AC-E 200 (Bruker BioSpin, Rheinstetten, Germany) and Bruker Avance DRX 400 spectrometers (Bruker BioSpin, Rheinstetten, Germany). Chemical shifts are given in ppm in δ scale and referred to CHCl₃ (δH at 7.26 ppm) and to CDCl₃ (δC 77.00 ppm), respectively. Coupling constants (J) are reported in Hertz (Hz). The H, H-COSY, H, C-HSQC and H, C-HMBC experiments were recorded using standard pulse sequences, in the version with z-gradients, as delivered by Bruker Corporation (Bruker BioSpin, Rheinstetten, Germany). Carbon substitution degrees were established by the DEPT pulse sequence. For analytical TLC, Sorbil silica-gel plates were used. The TLC plates were sprayed with conc. H₂SO₄ and heated at 80°C for 5 min. Column chromatography was carried out on Across silica gel (60–200 mesh) using petroleum ether (PE) (b.p. 40–60°C) and the gradient mixture of PE and
EtOAc. All solvents were purified and dried by standard techniques before use. Solutions in organic solvents were dried over anhydrous Na₂SO₄, filtered and evaporated under reduced pressure.

3.1.1. (1S,2R)-2-Hydroxy-1,3,7,7-tetramethyl-5-oxobicyclo[4.4.0]dec-3-en-2-ylmethyl acetate (8)

To a solution of 7 (100 mg, 0.40 mmol), prepared by the procedure of Vlad et al. (2013), in dry Py (5 mL), Ac₂O (0.5 mL) was added and the resulted mixture was stirred overnight at room temperature. Then the reaction mixture was diluted with water (30 mL) and extracted with diethyl ether (3 × 20 mL). After solvent removal the crude product (119 mg) was subjected to column chromatography on SiO₂ (12 g, eluent: PE–EtOAc 4:1) to afford 8 (112 mg, 96%) as white solid (MeOH), m.p. 87–88°C, [α]D²⁰ = 9.5 (c = 1.0, CHCl₃); IR (CHCl₃) ν 3620, 3505, 2923, 2950, 1755, 1674, 1230, 901 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz, ppm): δ 5.76 (1H, d, 1.2 Hz, H-7), 4.38 (1H, d, 12.4 Hz) and 4.26 (1H, d, 12.4 Hz, H-11), 2.81 (1H, s, H-5), 2.14 (3H, s, OAc), 1.94 (3H, d, 1.6 Hz, H-12), 1.20 (3H, s, H-13), 1.03 (3H, s, H-14); ¹³C NMR (CDCl₃, 100 MHz, ppm): δ 199.7 (C-6), 170.9 (C-νO), 152.9 (C-8), 129.9 (C-7), 75.1 (C-9), 64.7 (C-11), 55.3 (C-5), 45.6 (C-10), 33.8 (C-14), 32.2 (C-4), 31.9 (C-1), 21.8 (C-13), 21.1 (OAc), 19.80 (C-12), 18.1 (C-2), 17.9 (C-15); C₁₇H₂₆O₄ found (%) C, 69.58; H, 9.05; required (%) C, 69.36; H, 8.90.

3.1.2. (1S,2S)-3-Bromomethyl-2-hydroxy-1,7,7-trimethyl-5-oxobicyclo[4.4.0]dec-3-en-2-ylmethyl acetate (9)

To a solution of 8 (200 mg, 0.68 mmol) in dry CCl₄ (10 mL), NBS (363 mg, 2.04 mmol) was added and the resulted mixture was refluxed for 9 h. After cooling, the reaction mixture was filtered and the solvent removed to yield the crude product (260 mg), which was purified by column chromatography on SiO₂ (23 g, eluent: PE–EtOAc 4:1) to afford 9 (230 mg, 91%) as white solid (MeOH), m.p. 80–81°C; [α]D²⁰ = -16.7 (c = 0.6, CHCl₃); IR (CHCl₃) ν 3578, 2954, 2930, 1730, 1675, 1350, 1210, 1015, 780 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz, ppm): δ 6.03 (1H, s, H-7), 4.54 (1H, d, 12.4 Hz) and 4.38 (1H, d, 12.4 Hz, H-11), 4.19 (1H, d, 11.2 Hz) and 4.13 (1H, d, 11.2 Hz, H-12), 2.96 (1H, s, H-5), 2.18 (3H, s, OAc), 2.04–1.17 (7H, m), 1.18 (3H, s, H-13), 1.02 (3H, s, H-14); ¹³C NMR (CDCl₃, 100 MHz, ppm): δ 199.7 (C-6), 170.7 (C-νO), 149.9 (C-8), 132.9 (C-7), 75.3 (C-9), 64.1 (C-11), 55.6 (C-5), 46.2 (C-10), 42.2 (C-3), 33.5 (C-14), 32.2 (C-4), 31.8 (C-1), 31.4 (C-12), 21.7 (C-13), 21.1 (OAc), 18.0 (C-2), 17.8 (C-15); C₁₇H₂₅O₄Br found (%) C, 54.51; H, 6.60; Br, 21.13; required (%) C, 54.70; H, 6.75; Br, 21.41.

3.1.3. (1S,2S)-2-Hydroxy-1,7,7-trimethyl-2-methylcarbonyloxymethyl-5-oxobicyclo[4.4.0]dec-3-en-3-ylmethyl acetate (10)

The mixture of 9 (165 mg, 0.42 mmol) and KOAc (82 mg, 0.84 mmol) in dry dimethyl sulfoxide (DMSO) (5 mL) was stirred for 1 h at room temperature, then diluted with H₂O (10 mL) and extracted with Et₂O (3 × 15 mL). Next the organic layer was washed with H₂O (3 × 10 mL) and dried. After solvent removal the crude product was purified by column chromatography on SiO₂ (15 g, PE–EtOAc 4:1) to afford 10 (153 mg, 98%), as oil, [α]D²⁰ = 23.1 (c = 0.8, CHCl₃); IR (film): ν 3595, 3475, 2943, 1725, 1664, 1342, 1197, 1098 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz, ppm): δ 5.98 (1H, s, H-7), 4.81 (1H, d, 15.2 Hz) and 4.67 (1H, d, 15.2 Hz, H-11), 4.39 (1H, d, 12.4 Hz) and 4.29 (1H, d, 12.0 Hz, H-12), 2.88 (1H, s, H-5), 2.13 (3H, s, OAc), 2.12 (3H, s, OAc), 1.20 (3H, s, H-15), 1.15 (3H, s, H-13), 1.03 (3H, s, H-14); ¹³C NMR (CDCl₃,
100 MHz, ppm): δ 199.6 (C-6), 170.9 (C=O), 170.6 (C=O), 150.1 (C-8), 128.9 (C-7), 74.6 (C-9), 64.4 (C-11), 62.7 (C-12), 55.6 (C-5), 45.8 (C-10), 42.3 (C-3), 33.6 (C-14), 32.2 (C-4), 31.4 (C-1), 21.8 (C-13), 21.0 (OAc), 20.9 (OAc), 17.9 (C-15), 17.8 (C-2); C19H28O6 found (%) C, 64.51; H, 7.73; required (%) C, 64.75; H, 8.00.

3.1.4. (5S,6S)-5-Hydroxy-4,5-di(hydroxymethyl)-6,10,10-trimethylbicyclo[4.4.0]dec-3-en-2-one (11)

To a solution of 10 (130 mg, 0.37 mmol) in MeOH (1.5 mL), a saturated solution of K2CO3 in MeOH (7 mL) was added. The reaction mixture was stirred for 0.5 h at room temperature, diluted with H2O (15 mL) and extracted with Et2O (3 × 10 mL), then the organic layer was washed with H2O (3 × 10 mL) and dried. After solvent removal, the crude product (103 mg) was subjected to column chromatography on SiO2 (10 g, PE–EtOAc 7:3) to give 11 (98 mg, 99%) as white solid (MeOH), m.p. 121–122°C; literature not reported (Urones et al. 1997; Zhou et al. 2011); [α]D26.6 (c = 0.4, MeOH), literature [α]D20.1 = −26.6 (c = 0.4, MeOH) (Urones et al. 1997); IR (CHCl3): ν 3625, 3448, 2960, 1670, 1460, 1215, 1080 cm−1. 1H NMR (CDCl3, 400 MHz, ppm): δ 5.87 (1H, s, H-7), 4.49 (1H, d, 14.0 Hz) and 4.30 (1H, d, 14.0 Hz, H-12), 3.86 (2H, s, H-11), 2.87 (1H, s, H-5), 1.19 (3H, s, H-15), 1.15 (3H, s, H-13), 0.94 (3H, s, H-14). 13C NMR (CDCl3, 100 MHz, ppm): δ 200.7 (C-6), 153.4 (C-8), 128.8 (C-7), 141.8 (C-12), 33.5 (C-14), 32.2 (C-4), 31.2 (C-1), 21.8 (C-15), 17.7 (C-2); C15H24O4 found (%) C, 67.31; H, 9.23; required (%) C, 67.14; H 9.01.

3.1.5. (9aS,9bS)-9b-hydroxy-6,6,9a-trimethyl-1,3,5,5a,6,7,8,9,9a,9b-decahydrobenzo[e]-isobenzofuran-3,5-dione (12)

To a solution of 11 (30 mg, 0.112 mmol) in CH2Cl2 (3 mL), MnO2 (195 mg, 2.24 mmol) was added. The reaction mixture was stirred for 70 h at room temperature, then filtered through SiO2 (CH2Cl2). After solvent removal lactone 12 (26 mg, 93%) was obtained, as white solid (PE), m.p. 195–196°C, literature not reported (Kubo et al. 1983; Burke et al. 1991); [α]D21 = 35.16 (c = 0.3, CHCl3), literature not reported (Kubo et al. 1983; Burke et al. 1991); IR (CHCl3): ν 3434, 2974, 1770, 1625, 1490, 1190, 1140, 1115 cm−1. 1H NMR (CDCl3, 400 MHz, ppm): δ 6.50 (1H, s, H-7), 4.53 (1H, d, 10.2 Hz) and 4.37 (1H, d, 10.2 Hz, H-11), 2.96 (1H, s, H-5), 2.40–1.35 (2H, m), 1.18 (3H, s, H-15) 1.17 (3H, s, H-13), 1.08 (3H, s, H-14); 13C NMR (CDCl3, 100 MHz, ppm): δ 199.3 (C-6), 168.4 (C-12), 141.8 (C-8), 131.0 (C-7), 74.9 (C-9), 55.7 (C-5), 45.5 (C-10), 42.6 (C-3), 33.5 (C-14), 32.3 (C-4), 31.5 (C-1), 30.9 (C-11), 21.3 (C-13), 19.6 (C-15), 17.2 (C-2); C15H24O4 found (%) C, 67.96; H 7.48; required (%) C, 68.16; H 7.63.

3.2. Antimicrobial and antifungal activity

**Fungi:** A. niger ATCC 53346, P. frequentans ATCC 10110 and A. alternata ATCC 8741, and Gram-negative bacteria P. aeruginosa ATCC 27813 and Gram-positive B. polymyxa were provided by the American Type Culture Collection (ATCC, USA).

Compounds caspafugin and kanamycin, both from Liofilchem (Roseto degli Abruzzi, Italy), were used as standards for antifungal and antibacterial activity testing. After 48 h of incubation, a symmetrical inhibition ellipse centred along the strip was formed. The MIC is read directly from the scale in terms μg/mL, at the point where the edge of the inhibition ellipse intersects with the MIC test strip.

Sample solutions of 0.5%, 1% and 2% concentrations were obtained by dissolution of appropriate amounts of tested compounds 7–12 in fixed volumes of DMSO.
It must be mentioned that for fungi, Sabouraud agar medium with dextrose was used (4%, SDA), and for bacteria a Standard I nutrient agar medium was used, both from Merck (Schwalbach Hesse, Germany).

Microorganism suspensions were prepared using the method of successive agar dilutions according to the standard MIC (Usta et al. 2007) and their cultivation was carried out according to standard procedures (SR-EN 1275:2006 and NCCLS guidelines) (NCCLS 2003). The final charge-stock inoculum was prepared as $1 \times 10^{-6} \mu g/mL$ concentration and inoculated plates were incubated at 31°C for 7 days. First observations were made after 48 h and final observations after 7 days of incubation, establishing the MIC. Observations on the results were made by visual analysis, microscopy and photography, using a stereomicroscope Novex Ap-8 Euromex (Olimpus Europa Holding G.m.b.H., Hamburg, Germany) and Olympus SZY 160 microscope (Olympus Corporation, Shinjuku, Tokyo, Japan).

4. Conclusions

Thus, starting from (+)-larixol (3) via intermediate 6-oxo-7-drimen-9α,11-diol (7), the formal synthesis of (−)-pereniporin B (1) and (−)-cinnamosmolide (2) has been achieved in nine steps leading to lactone 12 in ~20% overall yield.

Acknowledgements

The support from the Project No. 264115 (STREAM) in the frame of EU funded FP7-REGPOT-2010-1 call is acknowledged by the authors from the ‘Petru Poni Institute’.

References

Burke SD, Shankaran K, Helber MJ. 1991. Synthesis of (+)-fragrolide and (−)-pereniporin B via vinylsilane terminated cationic cyclization. Tetrahedron Lett. 32:4655–4658.

Canonica L, Corbella A, Gariboldi G, Jommi G, Krepsinski J, Ferrari G, Casagrande C. 1969. Sesquiterpenoids of Cinnamosma fragrans baillon. Structure of cinnamolide, cinnamosmolide and cinnamodial. Tetrahedron. 25:3895–3902.

Canonica L, Corbella A, Jommi G, Krepsinski J. 1967. The structure of cinnamolide, cinnamosmolide and cinnamodial, sesquiterpenes with drimane skeleton from Cinnamosma fragrance baillon. Tetrahedron Lett. 23:2137–2141.

Fraga BM. 2013. Natural sesquiterpenoids. Nat Prod Rep. 30:1226–1264.

Garlaschelli L, De Tullio P, Vidari G. 1991. Synthetic studies on biologically active natural compounds. Part III. Stereospecific transformation of uvidin A into (−)-cinnamosmolide. Tetrahedron. 47:6769–6776.

Garlaschelli L, Vidari G. 1989. Synthetic studies on biologically active natural compounds. Part I: stereospecific transformation of uvidin a into (−)-cinnamodial. Tetrahedron. 45:7371–7378.

Harinantenaina L, Matsunami K, Otsuka H, Kawahata M, Yamaguchi K, Asakawa Y. 2008. Secondary metabolites of Cinnamosma madagascariensis and their α-glucosidase inhibitory properties. J Nat Prod. 71:123–126.

Hayes MA, Wrigley SK, Chetland I, Reynolds EE, Ainsworth AM, Renno DV, Latif MA, Cheng X-M, Hupe DJ, Charlton P, Doherty AM. 1996. Novel drimane sesquiterpene from Aspergillus ustus var. pseudodeflectus with andothelin receptor binding activity. J Antibiot. 49:505–512.

Jansen BJM, de Groot A. 2004. Occurrence, biological activity and synthesis of drimane sesquiterpenoids. Nat Prod Rep. 21:449–477.

Kida T, Shibahara H, Seto H. 1986. Structure of new antibiotics, pereniporins A and B, from a basidiomycete. J Antibiot. 39:613–615.

Kubo I, Matsumoto T, Kakoooko AB, Mubiru NK. 1983. Structure of mukaadial, a molluscicide from the Warburgia plants. Chem Lett. 7:979–980.

Lagnel BMF, Morin C, de Groot A. 2000. Synthesis of drimanes from (+)-larixol. Synthesis. 13:1907–1916.

Mahmoud II, Kinghorn AD, Cordell GA, Farnsworth NR. 1980. Potencial anticancer agents. XVI. Isolation of bicyclofarnesane sesquiterpenoids from Capsicodendron dinisii. J Nat Prod. 43:365–371.

Mills JS. 1973. Diterpenes of Larix oleoresins. Phytochemistry. 12:2407–2412.

Mori K, Takaishi H. 1989. Synthesis of (−)-pereniporins A and B, sesquiterpene antibiotics from a basidiomycete. Liebig's Ann Chem. 9:939–943.
Morioka H, Ishihara M, Takezawa M, Hirayama K, Suzuki E, Komoda Y, Shibai H. 1985. A new differentiation inducer of friend leukemia cells, trichostatic acid. Agric Biol Chem. 49:1365–1370.
Naito T, Nakata T, Akita H, Oishi T. 1980. Synthesis of (±)-cinnamodial and (±)-cinnamosmolide. Chem Lett. 9:445–446.
National Committee on Clinical Laboratory Standards [NCCLS]. 2003. Antimicrobial Susceptibility Standards (ATS), for M7 (CMI) and M100. Standard methods for antifungal susceptibility testing M51-P.
Rajab MS, Ndégva JM. 2000. 11α-Hydroxy muzigadiolide, a novel drimane sesquiterpene from the steam bark of Warburgia ugandensis. Bull Chem Soc Ethiop. 14:45–49.
Urones JG, Diez D, Gomez PM, Marcos IS, Basabe P, Moro RF. 1997. Chemistry of zamoranic acid. Part 10. Homochiral hemisynthesis of pereniporin A. J Chem Soc Perkin Trans. 1:1815–1818.
Urones JG, Marcos IS, Perez BG, Diez D, Lithgow AM, Gomez PM, Basabe P, Garrido NM. 1994. Chemistry of zamoranic acid. Part V. Homochiral semisynthesis of active drimanes: pereniporin B, polygodial and warburganal. Tetrahedron. 50:10995–11012.
Usta A, Yaşar A, Yılmaz N, Güleç C, Yaylı N, Karaoğlu ŞA, Yayli N. 2007. Synthesis, configuration, and antimicrobial properties of novel substituted and cyclized 2',3'-thiazachalcones. Helv Chim Acta. 90:1482–1490.
Vlad PF, Ciocarlan A, Coltsa M, Edu C, Biriiac A, Barba A, Deleanu C, Nicolescu A, D’Ambrosio M, De Groot A. 2013. Synthesis of (−)-albrassitriol and (−)-6-epi-albrassitriol from (+)-larixol. Nat Prod Res. 27:809–817.
Zhou H, Zhu T, Cai S, Gu Q, Li D. 2011. Drimane sesquiterpenoids from the mangrove-derived fungus Aspergillus ustus. Chem Pharm Bull. 59:762–766.